Linhua medical two inspection non-compliance dealer 3 employees involved in bribery case illegally obtain information

Suzhou Linhua Medical Equipment Co., Ltd. (hereinafter referred to as “Linhua medical”) will launch its first meeting on January 14. The company plans to list on the main board of Shanghai stock exchange this time, and issue no more than 40.04 million shares. The sponsor is Guotai Junan Securities Co., Ltd. Linhua medical plans to raise 601 million yuan, of which 327 million yuan will be used for the technical transformation project of automatic production of indwelling needle, 76.17 million yuan will be used for the technical transformation project of medical product research and development, 42.671 million yuan will be used for the information platform construction project, and 156 million yuan will be used for the marketing service network construction project. < / P > < p > from 2016 to 2019, the operating income of Linhua medical was 496 million yuan, 603 million yuan, 688 million yuan and 792 million yuan respectively, the main business income was 496 million yuan, 603 million yuan, 687 million yuan and 792 million yuan respectively, and the cash received from selling goods and providing services was 597 million yuan, 692 million yuan, 808 million yuan and 914 million yuan respectively. < / P > < p > from 2016 to 2019, the net profit of Linhua medical was 116 million yuan, 168 million yuan, 174 million yuan and 207 million yuan respectively, the net profit attributable to the parent was 116 million yuan, 168 million yuan, 173 million yuan and 207 million yuan respectively, and the net cash flow from operating activities was 198 million yuan, 168 million yuan, 204 million yuan and 248 million yuan respectively. < / P > < p > from 2016 to 2019, the total assets of Linhua medical were 692 million yuan, 848 million yuan, 995 million yuan and 1169 million yuan respectively, and the total liabilities were 124 million yuan, 144 million yuan, 178 million yuan and 219 million yuan respectively. < / P > < p > from 2016 to 2019, the cash paid by Linhua medical investment was 197 million yuan, 241 million yuan, 450 million yuan and 731 million yuan respectively. From 2017 to 2019, the cash paid by Linhua medical investment was the purchase of financial products. < / P > < p > from 2016 to 2019, the turnover rate of accounts receivable of Linhua medical was 132.70 times, 81.12 times, 60.72 times and 74.49 times respectively, and the average value of comparable companies in the same industry was 4.24 times, 4.13 times, 4.81 times and 4.21 times respectively. < / P > < p > from 2016 to 2019, the inventory turnover rate of Linhua medical was 5.19 times, 4.79 times, 4.40 times and 3.86 times respectively, and the average of comparable companies in the same industry was 3.53 times, 3.22 times, 3.65 times and 3.74 times respectively. < / P > < p > from 2016 to 2019, the business income of Linhua medical indwelling needle was 446 million yuan, 518 million yuan, 580 million yuan and 677 million yuan respectively, accounting for 89.90%, 85.85%, 84.48% and 85.48% of the company’s main business income. Linhua medical said that the company’s operating income is more dependent on indwelling needle products. If there are problems in the sales of indwelling needle products, it will bring greater risks to the company’s operation. < / P > < p > from 2016 to 2019, the average unit price of Linhua medical indwelling needle was 11.70 yuan / piece, 12.12 yuan / piece, 11.78 yuan / piece and 11.83 yuan / piece respectively. Among them, the average unit price of ordinary closed indwelling needle was 6.96 yuan / piece, 7.07 yuan / piece, 7.00 yuan / piece, 7.19 yuan / piece respectively; the average unit price of positive pressure needle free connection indwelling needle was 18.11 yuan / piece, 18.60 yuan / piece, 18.23 yuan / piece, 17.80 yuan / piece respectively; the average unit price of positive pressure needle was 26.08 yuan / piece, 23.07 yuan / piece, 21.63 yuan / piece, 13.03 yuan / piece respectively; the average unit price of other indwelling needles was 26.08 yuan / piece, 23.07 yuan / piece, 21.63 yuan / piece, 13.03 yuan / piece respectively The unit price is 12.04 yuan / piece, 13.18 yuan / piece, 13.17 yuan / piece and 13.03 yuan / piece respectively. It can be seen from the above data that the overall average unit price of Linhua medical indwelling needle increased in 2017, and the average unit price in 2018 and 2019 was lower than that in 2017, among which the average unit price of positive pressure needle free connecting indwelling needle and positive pressure anti acupuncture indwelling needle decreased in 2018 and 2019. < / P > < p > Lin Hua medical said that the company’s production capacity in 2019 increased significantly compared with that in 2018, but the company’s production did not increase rapidly, resulting in the capacity utilization rate falling to 80.09%. < p > < p > in response to an interview with China Economic Net, Lin Hua medical said that after the completion of the fund-raising project, the company has 10000 automatic production lines. At the same time, the company has 10000 manual production lines. After the project is completed, the annual sales expenses of Linhua medical are 155 million yuan, 176 million yuan, 203 million yuan and 242 million yuan, accounting for 31.19%, 29.25%, 29.56% and 30.53% of the operating income respectively. < / P > < p > the reporter of China Economic Net interviewed the company about the high sales expense rate of Linhua medical. The company replied that the domestic distribution of the company adopts the sales mode of “distribution + professional promotion”, attaches great importance to the guiding role of marketing team promotion service for terminal use, and has established a professional marketing team of 400 people, of which more than 45% have medical or medical professional degrees, which is a professional marketing team Dealers and end users provide professional services, technical guidance and after-sales service, so the salary of sales staff is higher. At the same time, the company has adopted a positive sales strategy, giving a higher proportion of bonus to the company’s sales staff. < / P > < p > from 2016 to 2018, the average R & D expense rates of comparable listed companies of Linhua medical were 3.11%, 3.05% and 3.38% respectively. < / P > < p > Linhua medical first submitted the prospectus on December 10, 2019. According to the prospectus, on June 26, 2019, Han houquan resigned as the company’s chief financial officer for personal reasons. On July 26, 2019, Linhua medical held the fifth meeting of the second board of directors and agreed to appoint Zhang Guoliang as the company’s chief financial officer. Han houquan was appointed financial director of Linhua medical on February 17, 2017. < p > < p > Linhua medical said that as of December 31, 2019, the goodwill in the company’s consolidated statements was 16.7792 million yuan, which was caused by the merger and acquisition of Jiaxing Meisen by Linhua medical in February 2017. < / P > < p > the company controls 90% of the equity of Jiaxing Meisen. On the merger day, the fair value share of the combined party’s identifiable net assets is 3.4367 million yuan, and the merger consideration is 26.1 million yuan. For the part of the merger consideration higher than the total fair value of Jiaxing Meisen’s identifiable net assets, the goodwill is 22.6633 million yuan on the merger day. According to the requirements of the accounting standards for Business Enterprises No. 8 – asset impairment, the goodwill formed by the acquisition of Jiaxing Meisen by the issuer has been tested for impairment on the book value as of December 31, 2019, and the provision for asset impairment of the goodwill formed by the acquisition of Jiaxing Meisen is 5.8841 million yuan. < / P > < p > If Jiaxing Meisen’s business condition deteriorates further, the related goodwill may be further impaired, which will have an adverse impact on the company’s performance. According to the first instance criminal judgment of the crime of accepting bribes on behalf of dobu issued by the judicial document website on December 26, 2019, from 2009 to 2016, dobu took advantage of his position to help Li, a distributor of Jiangsu shengrenyuan medical device Co., Ltd., go through the procedures of putting medical consumables in and out of the warehouse and continue to get Linhua indwelling needle as an authorized agent in Bazhou hospital, and successively accepted the help from Li 290000 yuan in cash. According to the criminal judgment of the first instance of the crime of supporting someone to accept bribes issued by the judicial document website on June 21, 2016, witness Huang’s testimony confirmed that in order to sell drugs and medical consumables in Guidong County People’s Hospital from 2008 to 2012, he gave a total of 42000 yuan to the director of pharmacy and equipment department of Guidong County People’s hospital. Among them, in November 2011, in order to sell 2000 Linhua brand indwelling needles to Guidong County People’s Hospital, he once found Fu in Chenzhou Shenxiang 4S shop and gave him 10000 yuan. After that, he helped to purchase 2000 Linhua brand indwelling needles at a certain place in Huang, and helped to handle the storage procedures of consumables. < p > < p > according to the criminal judgment of the first instance of bribery of Xinyu ChuangSheng Trading Co., Ltd. and WU Weimin unit issued by the judicial document website on April 30, 2020, the power of attorney confirms the judgment. According to the criminal judgment of the first instance of bribery of Xinyu ChuangSheng Trading Co., Ltd. and WU Weimin unit issued by the judicial document website on April 30, 2020, the power of attorney confirms that many companies successively authorize Xinyu ChuangSheng Trading Co., Ltd Trade Co., Ltd. in Xinyu people’s hospital sales of the company’s equipment. < / P > < p > the reporter of China Economic Net interviewed Linhua medical on the business bribery cases of dealers. The company replied that Linhua medical is a medical device manufacturer with nearly 1000 dealers. The relevant cases only involve the behavior of individual dealers and have nothing to do with Linhua medical. < / P > < p > in addition to the commercial bribery case involving dealers, an employee of Linhua medical also committed the crime of infringing citizens’ personal information, and was sentenced to one year’s imprisonment, suspended for one year, and fined 60000 yuan. < p > < p > according to the first instance criminal judgment of Shi Li and Li Fuling for infringing citizens’ personal information published on June 30, 2019, the defendant Bai Zongyu, product specialist of Suzhou Linhua medical device sales Co., Ltd., was detained on November 30, 2017 for suspected infringing citizens’ personal information, and was released on bail by Hebei Branch of Tianjin Public Security Bureau on January 5, 2018 On August 21 of the same year, the people’s Procuratorate of Hebei District of Tianjin city decided to be on bail pending trial, and on February 19, 2019, the people’s court decided to be on bail pending trial. < / P > < p > from November 1, 2015 to September 2017, the defendants Shi Li, Li Fuling, Gao Ying, Bai Zongyu, Yang Kun, Zhang Xiaohui and Chen Chong illegally obtained citizen information including personal name, home address, contact number and due date of birth from others through email or QQ chat tools, and then sold or provided it to others. < / P > < p > from November 1, 2015 to July 2017, the defendant Shi Li illegally obtained more than 55000 pieces of personal information from the defendant Li Fuling and others and sold them to Hao (sentenced) and others. During the period from November 1, 2015 to September 2017, the defendant Li Fuling illegally obtained the above personal information of citizens from the defendants Bai Zongyu and Gao Ying, and sold or provided more than 240000 pieces of personal information of citizens to others. From November 1, 2015 to August 2017, the defendant Gao Ying illegally obtained more than 5400 pieces of personal information from the defendant Bai Zongyu and provided it to the defendant Li Fuling. During the period from November 1, 2015 to December 2017, the defendant Bai Zongyu illegally obtained the above personal information from others and sold it to the defendant Li Fuling and others, with a total of more than 15000 pieces of personal information sold. < / P > < p > the people’s Court of Hebei District in Tianjin sentenced Bai Zongyu to one year’s imprisonment, one year’s probation and a fine of 60000 yuan. < / P > < p > the reporter of China Economic Net interviewed Linhua medical on employees’ illegal access to citizens’ personal information. The company replied that the case involved was personal behavior and had nothing to do with the company. < / P > < p > according to the prospectus, Linhua medical and its subsidiary Beijing Yuetong have two administrative punishments. Among them, the company’s illegal behavior is that the content of the product description does not include the production date, and Beijing Yuetong’s illegal behavior is that the product description and label are inconsistent with the registered or filed content. < / P > < p > on July 23, 2019, Beijing municipal market supervision and Administration Bureau issued the decision on administrative punishment (JXZ [2019] No. 5) to Beijing Yuetong, which identified that the approved “scope of application” in the product manual of Beijing Yuetong was marked as “product structure and composition”, which was inconsistent with the approved content and belonged to the medical device whose production manual and label did not meet the requirements, Beijing Yuetong was ordered to immediately stop the production of ZS2 series implantable drug delivery devices whose instructions and labels did not meet the requirements, and was fined 30000 yuan. < / P > < p > on December 17, 2019, Jiangsu Provincial Drug Administration issued the decision on administrative punishment to Linhua medical (syjx [2019] No. 1), which confirmed that the contents of the product manual of disposable sterile syringe with needle in Linhua medical stock did not include the production date, and was fined 20000 yuan by Jiangsu provincial drug administration.

Related Posts: